LY3502970
Evidence Grade C — Moderate human evidence. 77 published studies, 48 human. 43 registered clinical trials.
Orforglipron is a once-daily pill in late-stage development by Eli Lilly that activates the same GLP-1 receptor targeted by injectable treatments like semaglutide and tirzepatide. It is not a peptide — it is a small molecule — but it could become the first oral non-peptide GLP-1 treatment for obesity and diabetes, potentially offering a far more convenient alternative to weekly injections with no cold-chain storage requirements.
77 published studies: 48 human, 0 animal, 0 in-vitro, 40 reviews
Orforglipron is in Phase III development (not yet approved). Phase II results (272 patients, 36 weeks) showed up to 14.7% weight loss. Phase III results (ATTAIN-1, 3,127 patients, 72 weeks) showed 11–12% weight loss, which is less than injectable GLP-1 agonists but achieved with a once-daily pill.
Orforglipron is not a peptide. Its significance is in potentially making GLP-1-based obesity treatment available in pill form without the cold-chain storage and injection requirements of current peptide-based treatments. Phase III trials for type 2 diabetes are also ongoing.
Orforglipron binds a different site on the GLP-1 receptor than peptide agonists — a hydrophobic pocket within the receptor's transmembrane domain rather than the exterior peptide-binding site. It is a partial agonist biased toward the cAMP signalling pathway, which may reduce receptor desensitisation compared to full agonists. Despite its different binding mode, it produces the same downstream metabolic effects: appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion.
Phase III results (ATTAIN-1, 3,127 patients) showed 11-12% weight loss at 72 weeks — less than injectable GLP-1 agonists but achieved with a simple daily pill. A head-to-head trial showed superiority over oral semaglutide (Rybelsus) for blood sugar control. A regulatory filing was submitted in December 2025, with potential approval in 2026. Orforglipron's weight loss is lower than injectable competitors like CagriSema (23%) and tirzepatide (22.5%), positioning it primarily as an oral-first option for patients who prefer pills over injections, or as a step before escalating to injectables. The lack of food or water restrictions (unlike oral semaglutide) and room-temperature storage are meaningful practical advantages.
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Liraglutide is marketed as Victoza for type 2 diabetes (approved 2010) and Saxenda for weight management (approved 2014). The LEADER trial, involving over 9,300 patients followed for nearly four years, established that liraglutide reduced the risk of major cardiovascular events by 13% — a landmark finding that helped establish GLP-1 treatments as a class with heart benefits. Saxenda is also approved for adolescents aged 12 and older. While historically significant, liraglutide has been substantially surpassed by newer agents. In a direct comparison, semaglutide achieved 15.8% weight loss compared to liraglutide's 6.4%. Liraglutide remains relevant as a lower-intensity option and as a benchmark against which newer treatments are measured. It has over a decade of real-world safety data, making it one of the best-understood medications in this class.
Setmelanotide is marketed as Imcivree (Rhythm Pharmaceuticals; approved November 2020 for POMC, PCSK1, or LEPR deficiency; June 2022 for Bardet-Biedl syndrome; December 2024 expanded to patients aged 2 years and older). Genetic testing confirming an eligible mutation is required before treatment. In patients with POMC or PCSK1 deficiency, approximately 80% achieved at least 10% weight loss in clinical trials. In Bardet-Biedl syndrome, 32.3% achieved the same threshold. The most common side effects are injection-site reactions and skin darkening (due to the melanocortin pathway's connection to pigmentation). Setmelanotide exemplifies precision medicine — it is highly effective in the specific genetic populations it targets but is not indicated for common obesity.
HGH Fragment 176-191 has no marketing authorisation. A Phase IIa trial in obesity (approximately 300 patients) failed to demonstrate statistically significant weight loss at any dose tested. The clinical development programme was discontinued. The disconnect between animal data (which showed significant fat reduction in obese mice) and the failed human trial is the defining feature of this compound's development history. Products available through unregulated channels lack pharmaceutical quality assurance. The failed Phase II trial represents the highest level of clinical evidence available.
